title: Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.
abstract: Bendamustine has achieved widespread international regulatory approval and is a standard agent for the treatment for chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma and multiple myeloma. Since approval, the number of indications for bendamustine has expanded to include aggressive non-Hodgkin lymphoma and Hodgkin lymphoma and novel targeted therapies, based on new bendamustine regimens/combinations, are being developed against CLL and lymphomas. In 2010, an international panel of bendamustine experts met and published a set of recommendations on the safe and effective use of bendamustine in patients suffering from hematologic disorders. In 2014, this panel met again to update these recommendations since the clarification of issues including optimal dosing and management of bendamustine-related toxicities. The aim of this report is to communicate the latest consensus on the use of bendamustine, permitting the expansion of its safe and effective administration, particularly in new combination therapies.
authors.affiliation: a Lombardi Comprehensive Cancer Center, Georgetown University Hospital , Washington , DC , USA ;
authors.forename: Bruce D
authors.initials: BD
authors.lastname: Cheson
authors.affiliation: b Schwarzwald-Baar Clinic, University of Freiburg , Villingen-Schwenningen , Germany ;
authors.forename: Wolfram
authors.initials: W
authors.lastname: Brugger
authors.affiliation: c University Hospital, University of Basse-Normandie , Caen , France ;
authors.forename: Gandhi
authors.initials: G
authors.lastname: Damaj
authors.affiliation: d Medical Clinic, University Hospital of Munich , Munich , Germany ;
authors.forename: Martin
authors.initials: M
authors.lastname: Dreyling
authors.affiliation: e University of Wisconsin School of Medicine and Public Health , Madison , WI , USA ;
authors.forename: Brad
authors.initials: B
authors.lastname: Kahl
authors.affiliation: f Center for Hematology, Department of Medicine Huddinge , Karolinska Institutet , Stockholm , Sweden ;
authors.forename: Eva
authors.initials: E
authors.lastname: Kimby
authors.affiliation: g Department of Hematology , Tokai Central Hospital , Gifu , Japan ;
authors.forename: Michinori
authors.initials: M
authors.lastname: Ogura
authors.affiliation: h Department of Oncology and Hematology , Krankenhaus Nordwest , Frankfurt , Germany ;
authors.forename: Eckhart
authors.initials: E
authors.lastname: Weidmann
authors.affiliation: i Klinikum Schwabing, Academic Teaching Hospital of University of Munich , Munich , Germany ;
authors.forename: Clemens-Martin
authors.initials: CM
authors.lastname: Wendtner
authors.affiliation: j Institute of Hematology, University of Bologna , Bologna , Italy.
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069461:Bendamustine Hydrochloride / Q000627:therapeutic use*; D003245:Consensus Statements as Topic; D019468:Disease Management; D018450:Disease Progression; D004351:Drug Resistance; D006402:Hematologic Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D019337:Hematologic Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D006801:Humans; D012008:Recurrence; D019233:Retreatment
chemical_list: D018906:Antineoplastic Agents, Alkylating; D000069461:Bendamustine Hydrochloride
keywords: Bendamustine; CLL; Hodgkin; NHL; multiple myeloma